SG10202012188VA - Aldose reductase inhibitors and methods of use thereof - Google Patents

Aldose reductase inhibitors and methods of use thereof

Info

Publication number: SG10202012188VA
Authority: SG; Singapore
Prior art keywords: methods; reductase inhibitors; aldose reductase; aldose; inhibitors
Prior art date: 2016-06-21

Application number

SG10202012188VA

Inventor

Andrew Wasmuth

Donald W Landry

Original Assignee

Univ Columbia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-21

Filing date

2017-06-21

Publication date

2021-01-28

2017-06-21 Application filed by Univ Columbia filed Critical Univ Columbia

2021-01-28 Publication of SG10202012188VA publication Critical patent/SG10202012188VA/en

Links

239000003288 aldose reductase inhibitor Substances 0.000 title 1
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations

SG10202012188VA 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof SG10202012188VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662352784P	2016-06-21	2016-06-21

Publications (1)

Publication Number	Publication Date
SG10202012188VA true SG10202012188VA (en)	2021-01-28

Family

ID=60783884

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202012188VA SG10202012188VA (en)	2016-06-21	2017-06-21	Aldose reductase inhibitors and methods of use thereof
SG11201810642XA SG11201810642XA (en)	2016-06-21	2017-06-21	Aldose reductase inhibitors and methods of use thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201810642XA SG11201810642XA (en)	2016-06-21	2017-06-21	Aldose reductase inhibitors and methods of use thereof

Country Status (23)

Country	Link
US (5)	US10150779B2 (en)
EP (3)	EP3352754B1 (en)
JP (3)	JP6895464B2 (en)
CN (1)	CN109310674B (en)
AU (3)	AU2017281082B2 (en)
BR (1)	BR112018076244A2 (en)
CA (1)	CA3025081A1 (en)
DK (2)	DK3352754T3 (en)
ES (2)	ES2836500T3 (en)
FI (1)	FI3757107T3 (en)
HK (1)	HK1259379A1 (en)
HR (2)	HRP20231563T1 (en)
HU (2)	HUE052101T2 (en)
IL (3)	IL283809B2 (en)
LT (2)	LT3757107T (en)
MX (2)	MX2018016122A (en)
PL (1)	PL3757107T3 (en)
PT (2)	PT3757107T (en)
RS (1)	RS61239B1 (en)
SG (2)	SG10202012188VA (en)
SI (2)	SI3352754T1 (en)
WO (1)	WO2017223179A1 (en)
ZA (1)	ZA201808506B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
SI3352754T1 (en) *	2016-06-21	2021-03-31	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and methods of use thereof
CA3071114A1 (en) *	2017-07-28	2019-01-31	Applied Therapeutics Inc.	Compositions and methods for treating galactosemia
EP3924060A4 (en) *	2019-02-12	2023-03-22	Applied Therapeutics, Inc.	Methods for treating cutaneous aging
JP2022519944A (en) *	2019-04-01	2022-03-25	アプライドセラピューティクスインコーポレイテッド	Inhibitor of aldose reductase
AU2020363699A1 (en) *	2019-10-08	2022-05-26	Applied Therapeutics, Inc.	Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
WO2021202523A1 (en)	2020-03-31	2021-10-07	Applied Therapeutics, Inc.	Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
JP2023524504A (en)	2020-05-01	2023-06-12	アプライドセラピューティクス，インコーポレイテッド	Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
US20240033263A1 (en) *	2021-03-18	2024-02-01	Banavara MYLARI	Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0189272A3 (en) *	1985-01-17	1987-08-19	Fujisawa Pharmaceutical Co., Ltd.	New furanone derivatives, processes for preparation thereof and use thereof
CA1299178C (en)	1985-11-07	1992-04-21	Banavara Lakshmana Mylari	Heterocyclic oxophtalazinyl acetic acids
ES2032749T3 (en)	1985-11-07	1993-03-01	Pfizer Inc.	OXOFTALAZINYL-HETERO-CYCLIC ACIDS.
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) *	1987-06-09	1989-09-19	Pfizer Inc.	Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en)	1988-01-19	1989-07-27	Pfizer Inc.	1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en)	1989-05-11	1990-09-04	Pfizer Inc.	Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (en)	1989-06-05	1990-12-07	Union Pharma Scient Appl	New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors
US5304557A (en)	1989-12-15	1994-04-19	Pfizer Inc.	Substituted oxoophthalazinyl acetic acids and analogs thereof
JPH0495025A (en)	1990-08-08	1992-03-27	Asahi Chem Ind Co Ltd	Aldose reductase inhibitor
WO1994007867A1 (en) *	1992-09-28	1994-04-14	Pfizer Inc.	Substituted pyrimidines for control of diabetic complications
WO1997008126A1 (en)	1995-08-28	1997-03-06	American Home Products Corporation	Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents
AU9253798A (en) *	1997-09-23	1999-04-12	Novo Nordisk A/S	Modules of protein tyrosine phosphatases (ptpases)
YU59600A (en)	1998-03-31	2002-12-10	The Institute For Pharmaceutical Discovery Inc.	Substituted indolealkanoic acids
EP0982306A3 (en)	1998-08-21	2000-07-05	Pfizer Products Inc.	Polymorph of zopolrestat monohydrate
US6570013B2 (en)	2000-02-16	2003-05-27	Pfizer Inc	Salts of zopolrestat
HUP0303644A3 (en)	2001-03-30	2008-06-30	Pfizer Prod Inc	Pyridazinone-derivatives aldose reductase inhibitors, their use and pharmaceutical compositions containing them
WO2003061660A1 (en)	2002-01-23	2003-07-31	Eli Lilly And Company	Melanocortin receptor agonists
US20040047919A1 (en)	2002-06-13	2004-03-11	Board Of Regents, The University Of Texas System	Methods and compositions involving aldose reductase inhibitors
MXPA04012396A (en) *	2002-06-14	2005-06-17	Sato Fumihiko	Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers.
US7572910B2 (en)	2003-02-20	2009-08-11	Pfizer, Inc.	Pyridazinone aldose reductase inhibitors
US20070021366A1 (en)	2004-11-19	2007-01-25	Srivastava Satish K	Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
CN101143868A (en)	2007-09-04	2008-03-19	北京理工大学	Aldose reductase inhibitor structure and use
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
EP3192796B1 (en)	2010-07-16	2019-09-04	The Trustees of Columbia University in the City of New York	Aldose reductase inhibitors and uses thereof
CN102512407B (en)	2011-11-23	2014-05-21	中山大学	Application of utilizing beta-phenylalanine compounds as aldose reductase inhibitors
SI3352754T1 (en) *	2016-06-21	2021-03-31	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and methods of use thereof
US11329472B2 (en)	2018-07-20	2022-05-10	Texas Instruments Incorporated	Methods and apparatus to prevent undesired triggering of short circuit or over current protection

2017
- 2017-06-21 SI SI201730529T patent/SI3352754T1/en unknown
- 2017-06-21 LT LTEP20188323.8T patent/LT3757107T/en unknown
- 2017-06-21 EP EP17816127.9A patent/EP3352754B1/en active Active
- 2017-06-21 PL PL20188323.8T patent/PL3757107T3/en unknown
- 2017-06-21 WO PCT/US2017/038505 patent/WO2017223179A1/en active Application Filing
- 2017-06-21 HU HUE17816127A patent/HUE052101T2/en unknown
- 2017-06-21 LT LTEP17816127.9T patent/LT3352754T/en unknown
- 2017-06-21 MX MX2018016122A patent/MX2018016122A/en unknown
- 2017-06-21 AU AU2017281082A patent/AU2017281082B2/en active Active
- 2017-06-21 JP JP2018567299A patent/JP6895464B2/en active Active
- 2017-06-21 SI SI201731462T patent/SI3757107T1/en unknown
- 2017-06-21 RS RS20201463A patent/RS61239B1/en unknown
- 2017-06-21 SG SG10202012188VA patent/SG10202012188VA/en unknown
- 2017-06-21 DK DK17816127.9T patent/DK3352754T3/en active
- 2017-06-21 HR HRP20231563TT patent/HRP20231563T1/en unknown
- 2017-06-21 CN CN201780038647.5A patent/CN109310674B/en active Active
- 2017-06-21 EP EP23201547.9A patent/EP4316603A3/en active Pending
- 2017-06-21 DK DK20188323.8T patent/DK3757107T3/en active
- 2017-06-21 ES ES17816127T patent/ES2836500T3/en active Active
- 2017-06-21 BR BR112018076244-0A patent/BR112018076244A2/en active Search and Examination
- 2017-06-21 ES ES20188323T patent/ES2966094T3/en active Active
- 2017-06-21 CA CA3025081A patent/CA3025081A1/en active Pending
- 2017-06-21 PT PT201883238T patent/PT3757107T/en unknown
- 2017-06-21 IL IL283809A patent/IL283809B2/en unknown
- 2017-06-21 SG SG11201810642XA patent/SG11201810642XA/en unknown
- 2017-06-21 FI FIEP20188323.8T patent/FI3757107T3/en active
- 2017-06-21 HU HUE20188323A patent/HUE064911T2/en unknown
- 2017-06-21 PT PT178161279T patent/PT3352754T/en unknown
- 2017-06-21 IL IL304979A patent/IL304979A/en unknown
- 2017-06-21 EP EP20188323.8A patent/EP3757107B1/en active Active
2018
- 2018-04-24 US US15/961,288 patent/US10150779B2/en active Active
- 2018-11-06 US US16/182,169 patent/US10647726B2/en active Active
- 2018-12-10 IL IL263631A patent/IL263631B/en unknown
- 2018-12-18 MX MX2021014938A patent/MX2021014938A/en unknown
- 2018-12-18 ZA ZA2018/08506A patent/ZA201808506B/en unknown
2019
- 2019-01-31 HK HK19101747.3A patent/HK1259379A1/en unknown
2020
- 2020-03-31 US US16/835,876 patent/US10870658B2/en active Active
- 2020-11-02 US US17/086,699 patent/US11498925B2/en active Active
- 2020-11-30 HR HRP20201905TT patent/HRP20201905T1/en unknown
2021
- 2021-06-07 JP JP2021094883A patent/JP7368419B2/en active Active
- 2021-06-09 AU AU2021203801A patent/AU2021203801B2/en active Active
2022
- 2022-10-13 US US18/046,205 patent/US20230312599A1/en active Pending
2023
- 2023-06-30 AU AU2023204218A patent/AU2023204218A1/en active Pending
- 2023-10-12 JP JP2023176883A patent/JP2023171614A/en active Pending

Also Published As

Publication number	Publication date
CN109310674A (en)	2019-02-05
ES2836500T3 (en)	2021-06-25
IL283809B2 (en)	2024-01-01
IL283809B1 (en)	2023-09-01
PL3757107T3 (en)	2024-03-18
SG11201810642XA (en)	2019-01-30
ES2966094T3 (en)	2024-04-18
US10870658B2 (en)	2020-12-22
US20190300543A1 (en)	2019-10-03
HRP20201905T1 (en)	2021-01-22
FI3757107T3 (en)	2023-12-12
CN109310674B (en)	2022-07-08
ZA201808506B (en)	2020-05-27
RU2019101194A (en)	2020-07-23
EP3352754B1 (en)	2020-09-02
EP3352754A4 (en)	2019-04-17
DK3352754T3 (en)	2020-12-07
SI3352754T1 (en)	2021-03-31
US11498925B2 (en)	2022-11-15
RS61239B1 (en)	2021-01-29
AU2021203801B2 (en)	2023-04-06
LT3352754T (en)	2021-02-25
MX2021014938A (en)	2022-01-24
PT3757107T (en)	2023-12-14
EP4316603A2 (en)	2024-02-07
US20230312599A1 (en)	2023-10-05
US20180237451A1 (en)	2018-08-23
EP3757107A1 (en)	2020-12-30
US20210284652A1 (en)	2021-09-16
HUE064911T2 (en)	2024-04-28
PT3352754T (en)	2020-12-07
AU2021203801A1 (en)	2021-07-15
BR112018076244A2 (en)	2019-03-26
EP4316603A3 (en)	2024-04-17
HK1259379A1 (en)	2019-11-29
IL263631B (en)	2021-07-29
JP7368419B2 (en)	2023-10-24
JP6895464B2 (en)	2021-06-30
US10150779B2 (en)	2018-12-11
HUE052101T2 (en)	2021-04-28
US10647726B2 (en)	2020-05-12
JP2021130719A (en)	2021-09-09
HRP20231563T1 (en)	2024-03-15
LT3757107T (en)	2023-12-11
US20200283451A1 (en)	2020-09-10
CN115160339A (en)	2022-10-11
IL283809A (en)	2021-07-29
RU2019101194A3 (en)	2020-08-31
CA3025081A1 (en)	2017-12-28
EP3352754A1 (en)	2018-08-01
AU2017281082A1 (en)	2018-12-06
SI3757107T1 (en)	2024-02-29
JP2019518779A (en)	2019-07-04
DK3757107T3 (en)	2023-11-27
IL263631A (en)	2019-01-31
MX2018016122A (en)	2019-08-01
IL304979A (en)	2023-10-01
AU2017281082B2 (en)	2021-03-18
AU2023204218A1 (en)	2023-07-27
WO2017223179A1 (en)	2017-12-28
EP3757107B1 (en)	2023-10-25
JP2023171614A (en)	2023-12-01

Publication	Publication Date	Title
HK1259232A1 (en)	2019-11-29	Substituted inhibitors of menin-mll and methods of use
IL283809A (en)	2021-07-29	Aldose reductase inhibitors and methods of use thereof
EP3700527A4 (en)	2021-03-10	Papd5 inhibitors and methods of use thereof
HK1252693A1 (en)	2019-05-31	Inhibitors of egfr and methods of use thereof
HK1249513A1 (en)	2018-11-02	Fused-tricyclic inhibitors of kras and methods of use thereof
IL267291B (en)	2022-12-01	Ectonucleotidase inhibitors and methods of use thereof
EP3510040A4 (en)	2020-06-03	Ectonucleotidase inhibitors and methods of use thereof
EP3684361A4 (en)	2021-09-08	Substituted inhibitors of menin-mll and methods of use
EP3268369A4 (en)	2018-08-08	Anti-alphavbeta1 integrin inhibitors and methods of use
IL259801A (en)	2018-07-31	Inhibitors of ezh2 and methods of use thereof
IL252827A0 (en)	2017-08-31	Inhibitors of cellular necrosis and related methods
EP3445365A4 (en)	2019-10-16	Ezh2 inhibitors and uses thereof
EP3572400C0 (en)	2023-10-04	Ezh2 inhibitor and use thereof
IL274504A (en)	2020-06-30	Acss2 inhibitors and methods of use thereof
GB2562984B (en)	2019-04-03	Hydrate inhibitors and methods of use
EP3265476A4 (en)	2018-08-22	Protoxin-ii variants and methods of use
EP3177327A4 (en)	2018-03-14	Inhibitors of myh7b and uses thereof
EP3277304A4 (en)	2018-12-19	Protoxin-ii variants and methods of use
EP3717504A4 (en)	2021-10-20	Yeats inhibitors and methods of use thereof
EP3148986A4 (en)	2018-01-10	Arf6 inhibitors and methods of synthesis and use thereof
GB2562679B (en)	2022-06-08	Double-headed hydrate inhibitors and methods of use
EP3370763A4 (en)	2019-06-12	Cd200 inhibitors and methods of use thereof
IL266344A (en)	2019-06-30	Inhibitors of mtor-deptor interactions and methods of use thereof
IL261906A (en)	2018-10-31	Biomarkers of proteopathies and uses thereof
IL263379A (en)	2018-12-31	Gm-csf variants and methods of use